In Vino Vita, Fox Chase’s Signature Fundraising Event, Raises Over $1.5 Million for Cancer Research, Treatment and Prevention

Money from this year’s Special Pledge will fund a next-generation mobile screening unit that will build on Fox Chase’s three decades of experience as a leader in mobile cancer screening.
Money from this year’s Special Pledge will fund a next-generation mobile screening unit that will build on Fox Chase’s three decades of experience as a leader in mobile cancer screening.

PHILADELPHIA (November 8, 2021)—In Vino Vita, Fox Chase Cancer Center’s signature fundraising event, was held on October 30 at the National Constitution Center, and raised over $1.5 million for cancer research, treatment and prevention.

“This event played a major role in our ability to offer world-class cancer care to those who need it. Through the years, proceeds from In Vino Vita have allowed us to make a difference in the lives of our patients as well as clinical and research faculty,” said Richard I. Fisher, MD, the president and CEO of Fox Chase.

A highlight of the event was the presentation of the inaugural Fox Chase Corporate Philanthropy Award to West Pharmaceutical Services in recognition of their two decades of support for Fox Chase. The award was bestowed by J. Robert Beck, MD, professor emeritus at Fox Chase, who co-chaired the event with his wife Maggie Beck, PhD.

“Through the years, their fundraising efforts have supported some of our highest priority initiatives and most promising research projects,” Beck said. “From melanoma, blood and pancreatic cancer research to immunotherapy treatment, West has provided our scientists with remarkable opportunities to make a difference in the lives of cancer patients.”

“We are honored to receive this recognition from Fox Chase Cancer Center and grateful to serve as their partner, helping to make a difference in the fight against cancer,” said Eric Green, West President and CEO. “West is proud to be by the side of research centers like Fox Chase and look forward to what we can achieve together in the years to come.”

Fisher noted that funds from previous In Vino Vita events provided funding for such things as state-of-the-art infusion recliners, renovation and expansion of a surgical family waiting suite, outfitting of an immunotherapy laboratory, and the launch of 12 pilot research grants.

Money from this year’s Special Pledge will fund a next-generation mobile screening unit that will build on Fox Chase’s three decades of experience as a leader in mobile cancer screening. The new unit will offer screening for more types of cancer, 3-D mammography, and new initiatives, like vaccine distribution, phlebotomy, and collection of biospecimens and population data to advance cancer research.

“When I arrived at Fox Chase, I brought along my vision for this wine auction,” Fisher said at the event. “Today, In Vino Vita has become a premier wine event for the city of Philadelphia, and together, we have raised nearly $8.5 million towards our efforts. This is an incredible accomplishment, and one that would not be possible without your support.”

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427